![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CD37 |
Gene summary for CD37 |
![]() |
Gene information | Species | Human | Gene symbol | CD37 | Gene ID | 951 |
Gene name | CD37 molecule | |
Gene Alias | GP52-40 | |
Cytomap | 19q13.33 | |
Gene Type | protein-coding | GO ID | GO:0001772 | UniProtAcc | P11049 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
951 | CD37 | CA_HPV_1 | Human | Cervix | CC | 1.97e-02 | 1.12e-01 | 0.0264 |
951 | CD37 | CCI_1 | Human | Cervix | CC | 3.25e-07 | -6.55e-01 | 0.528 |
951 | CD37 | CCI_2 | Human | Cervix | CC | 1.54e-06 | -6.55e-01 | 0.5249 |
951 | CD37 | CCI_3 | Human | Cervix | CC | 7.02e-07 | -6.24e-01 | 0.516 |
951 | CD37 | CCII_1 | Human | Cervix | CC | 4.27e-14 | -6.55e-01 | 0.3249 |
951 | CD37 | Tumor | Human | Cervix | CC | 1.20e-34 | -6.55e-01 | 0.1241 |
951 | CD37 | sample1 | Human | Cervix | CC | 7.17e-08 | -5.97e-01 | 0.0959 |
951 | CD37 | sample3 | Human | Cervix | CC | 1.03e-36 | -6.53e-01 | 0.1387 |
951 | CD37 | H2 | Human | Cervix | HSIL_HPV | 8.65e-24 | -6.12e-01 | 0.0632 |
951 | CD37 | L1 | Human | Cervix | CC | 2.03e-09 | -5.37e-01 | 0.0802 |
951 | CD37 | T1 | Human | Cervix | CC | 1.27e-20 | -6.18e-01 | 0.0918 |
951 | CD37 | T2 | Human | Cervix | CC | 3.96e-06 | -6.55e-01 | 0.0709 |
951 | CD37 | T3 | Human | Cervix | CC | 2.69e-33 | -6.53e-01 | 0.1389 |
951 | CD37 | LZE4T | Human | Esophagus | ESCC | 5.35e-08 | 3.32e-01 | 0.0811 |
951 | CD37 | LZE7T | Human | Esophagus | ESCC | 6.44e-07 | 6.67e-01 | 0.0667 |
951 | CD37 | LZE8T | Human | Esophagus | ESCC | 1.66e-02 | 3.09e-01 | 0.067 |
951 | CD37 | LZE22D1 | Human | Esophagus | HGIN | 1.13e-02 | 5.49e-01 | 0.0595 |
951 | CD37 | LZE24T | Human | Esophagus | ESCC | 4.34e-05 | 3.63e-01 | 0.0596 |
951 | CD37 | LZE6T | Human | Esophagus | ESCC | 3.54e-14 | 7.58e-01 | 0.0845 |
951 | CD37 | C21 | Human | Oral cavity | OSCC | 1.07e-08 | 4.26e-01 | 0.2678 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04640 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
hsa046401 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD37 | SNV | Missense_Mutation | novel | c.209N>A | p.Gly70Asp | p.G70D | P11049 | protein_coding | tolerated(0.13) | possibly_damaging(0.625) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD37 | SNV | Missense_Mutation | novel | c.602T>A | p.Leu201His | p.L201H | P11049 | protein_coding | tolerated(0.35) | possibly_damaging(0.573) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD37 | SNV | Missense_Mutation | c.559N>G | p.Thr187Ala | p.T187A | P11049 | protein_coding | tolerated(0.42) | benign(0.003) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CD37 | SNV | Missense_Mutation | novel | c.757N>A | p.Gly253Ser | p.G253S | P11049 | protein_coding | tolerated(0.14) | possibly_damaging(0.691) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CD37 | SNV | Missense_Mutation | c.432C>G | p.Asp144Glu | p.D144E | P11049 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-DD-A4NQ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Targeted Molecular therapy | sorafenib | PD | |
CD37 | SNV | Missense_Mutation | c.286C>T | p.Leu96Phe | p.L96F | P11049 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-22-5485-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
CD37 | SNV | Missense_Mutation | c.539N>A | p.Ser180Tyr | p.S180Y | P11049 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-39-5019-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
CD37 | SNV | Missense_Mutation | c.662N>A | p.Ala221Glu | p.A221E | P11049 | protein_coding | tolerated(0.5) | benign(0.017) | TCGA-43-5668-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Other, specify in notesMAGE3-AS15-NSC-003 | clinical | PD | |
CD37 | SNV | Missense_Mutation | novel | c.749T>C | p.Leu250Pro | p.L250P | P11049 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-56-7730-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | unknown | PD |
CD37 | SNV | Missense_Mutation | novel | c.560C>G | p.Thr187Ser | p.T187S | P11049 | protein_coding | tolerated(0.25) | benign(0.038) | TCGA-85-8666-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
951 | CD37 | DRUGGABLE GENOME | IMGN529 | NARATUXIMAB EMTANSINE | ||
951 | CD37 | DRUGGABLE GENOME | antibody | 374883837 | ||
951 | CD37 | DRUGGABLE GENOME | TRU-016 | OTLERTUZUMAB | ||
951 | CD37 | DRUGGABLE GENOME | Otlertuzumab | OTLERTUZUMAB | ||
951 | CD37 | DRUGGABLE GENOME | BI-836826 | |||
951 | CD37 | DRUGGABLE GENOME | antibody | 374883838 | OTLERTUZUMAB | |
951 | CD37 | DRUGGABLE GENOME | antibody | 374883836 | ||
951 | CD37 | DRUGGABLE GENOME | TRU-016 | OTLERTUZUMAB |
Page: 1 |